Zoetis Inc. (ZTS)
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
- Ticker
- ZTS
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $34.02B
- 52-week range
- $68.77 - $132.49
Valuation
- Share price
- $85.57 (close of Nov 18, 2026)
- P/E (TTM)
- 14.05x
- Price to book
- 10.30x
- Price to free cash flow
- 15.22x
- Enterprise value
- $41.72B
- Book value per share
- $8.11
Price performance
| Period | Change |
|---|---|
| 1 day | +2.50% |
| 5 days | +3.63% |
| 1 month | +7.80% |
| 3 months | +15.70% |
| 6 months | +10.10% |
| Year to date | -31.99% |
| 1 year | -27.57% |
| 3 years | -51.05% |
| 5 years | -62.06% |
| 10 years | +71.52% |
| All time | +175.95% |
Short interest
- As of
- Oct 30, 2026
- Short % of float
- 4.67%
- Shares short
- 16.72M
- Days to cover
- 4.78
- Change since prior report
- -4.55%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed ZTS trades
Gilbert Ray Cisneros · Markwayne Mullin · Jefferson Shreve · Lisa McClain · Robert Bresnahan · Byron Donalds · Julie Johnson · Rick Larsen
Super investors holding ZTS
Christopher Davis (Davis Selected Advisers) · Ruane Cunniff (Ruane, Cunniff & Goldfarb L.P.) · Ken Griffin (Citadel) · First Eagle Investment (First Eagle Investment Management, LLC) · Mairs & Power (Mairs & Power Inc) · Tweedy Browne (Tweedy Browne Company LLC) · Sarah Ketterer (Causeway Capital Management LLC) · Ray Dalio (Bridgewater Associates) · Polen Capital Mgmt (Polen Capital Management LLC) · Hillman Capital (Hillman Capital Management, Inc)
Profitability and growth
- Return on equity
- 80.25%
- Return on invested capital
- 23.03%*
- Return on assets
- 17.28%
- Return on capital employed
- 27.07%*
- Gross margin
- 71.84%
- Net margin
- 28.23%
- EBITDA margin
- 42.98%
- Revenue growth
- 2.28%
- Net income growth
- 7.52%
- Free cash flow growth
- -0.65%
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 6.57%
- Current ratio
- 2.35x
- Net debt to EBITDA
- 2.00x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Revenue
- $9.47B
- Cost of revenue
- $2.67B
- Gross profit
- $6.80B
- EBITDA
- $4.07B
- Net income
- $2.67B
- Earnings per share
- $6.03
- Research and development
- $698.00M
- Interest expense
- $222.00M
- Shares outstanding
- 443.44M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $9.47B | $6.80B | $2.67B | $6.03 |
| 2024-12-31 | $9.26B | $6.54B | $2.49B | $5.47 |
| 2023-12-31 | $8.54B | $5.98B | $2.34B | $5.08 |
| 2022-12-31 | $8.08B | $5.63B | $2.11B | $4.51 |
| 2021-12-31 | $7.78B | $5.47B | $2.04B | $4.29 |
| 2020-12-31 | $6.67B | $4.62B | $1.64B | $3.44 |
| 2019-12-31 | $6.26B | $4.27B | $1.50B | $3.14 |
| 2018-12-31 | $5.83B | $3.91B | $1.43B | $2.96 |
| 2017-12-31 | $5.31B | $3.53B | $864.00M | $1.76 |
| 2016-12-31 | $4.89B | $3.22B | $821.00M | $1.66 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 71.84% | 28.23% | 80.25% | 23.03%* |
| 2024-12-31 | 70.62% | 26.86% | 52.12% | 23.63%* |
| 2023-12-31 | 70.03% | 27.43% | 46.96% | 21.96%* |
| 2022-12-31 | 69.63% | 26.16% | 48.01% | 18.67%* |
| 2021-12-31 | 70.38% | 26.20% | 44.83% | 19.93%* |
| 2020-12-31 | 69.18% | 24.54% | 43.41% | 16.71%* |
| 2019-12-31 | 68.18% | 23.96% | 55.39% | 18.42%* |
| 2018-12-31 | 67.19% | 24.52% | 65.35% | 18.87%* |
| 2017-12-31 | 66.55% | 16.28% | 48.38% | 15.39%* |
| 2016-12-31 | 65.92% | 16.80% | 54.77% | 16.51%* |
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $2.31B | $9.04B |
| 2024-12-31 | $1.99B | $5.22B |
| 2023-12-31 | $2.04B | $6.56B |
| 2022-12-31 | $3.58B | $6.55B |
| 2021-12-31 | $3.48B | $6.59B |
| 2020-12-31 | $3.60B | $6.59B |
| 2019-12-31 | $1.93B | $5.95B |
| 2018-12-31 | $1.70B | $6.44B |
| 2017-12-31 | $1.56B | $4.95B |
| 2016-12-31 | $727.00M | $4.47B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $2.28B | $83.00M |
| 2024-12-31 | $2.30B | $74.00M |
| 2023-12-31 | $1.62B | $60.00M |
| 2022-12-31 | $1.33B | $62.00M |
| 2021-12-31 | $1.74B | $58.00M |
| 2020-12-31 | $1.67B | $59.00M |
| 2019-12-31 | $1.33B | $67.00M |
| 2018-12-31 | $1.45B | $53.00M |
| 2017-12-31 | $1.12B | $44.00M |
| 2016-12-31 | $497.00M | $37.00M |
Dividend history
- Most recent payment
- Oct 30, 2026
- Paid in the last twelve months
- $2.12
| Payment date | Dividend per share |
|---|---|
| 2026-10-30 | $0.53 |
| 2026-07-20 | $0.53 |
| 2026-04-20 | $0.53 |
| 2026-01-20 | $0.53 |
| 2025-10-31 | $0.50 |
| 2025-07-18 | $0.50 |
| 2025-04-21 | $0.50 |
| 2025-01-21 | $0.50 |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-11-05 | Sep 2026 | $1.51 |
| 2026-08-06 | Jun 2026 | $1.84 |
| 2026-05-07 | Mar 2026 | $1.61 |
| 2026-02-12 | Dec 2025 | $1.40 |
| 2025-11-04 | Sep 2025 | $1.62 |
| 2025-08-05 | Jun 2025 | $1.62 |
| 2025-05-06 | Mar 2025 | $1.40 |
| 2025-02-13 | Dec 2024 | $1.37 |
Filings and sources
- Company website
- zoetis.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Viatris Inc (VTRS) · Teva Pharmaceutical Industries Ltd (TEVA) · Hims & Hers Health, Inc. (HIMS) · Haleon plc (HLN) · Novo Nordisk A S (NVO) · GSK plc (GSK) · McKesson Corp (MCK) · Organon & Co. (OGN)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades